- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02110641
Lifestyle, Exercise and Nutrition Study 2 (LEAN 2) (LEAN 2)
February 17, 2023 updated by: Yale University
Lifestyle, Exercise and Nutrition (LEAN) Study 2
The specific aims of this study are to determine the efficacy and cost-effectiveness of a weight loss program compared with usual care (control) treatment on 6-month changes in body weight, body fat, serum hormones, and breast tissue markers associated with prognosis in breast cancer survivors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
We will conduct a two-armed study comparing a combination of an in-person and telephone weight loss program compared to usual care/wait list in 100 breast cancer survivors.
Women will be randomized into one of the study arms using a random permuted block design.
Research staff collecting body composition data, as well as reviewing forms and entering data, will be blinded to the participant's study group.
Study Type
Interventional
Enrollment (Actual)
51
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- American Joint Committee on Cancer (AJCC) Stages 0-IIIC Breast Cancer
- BMI >25 kg/m2
- Completed surgery, chemotherapy and radiation at least 2 months ago
- Physically able to exercise
- Agrees to be randomly assigned to either weight loss or control
- Gives informed consent to participate in all study activities
- Able to come for baseline and 6-month clinic visits
- Mentally competent
Exclusion Criteria:
- Patients with double mastectomy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: In-Person or Telephone-Based Counseling
The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling.
Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6).
All lessons and diet and physical activity logs will be mailed to them at the beginning of the program.
Participants will record their daily diet and exercise in the logs.
|
The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy.
The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling).
The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
|
No Intervention: Usual Care/Wait List
At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery.
They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Mass Index (BMI)
Time Frame: 6 months
|
BMI will be calculated using weight and height measurements (weight (kg)/height (m)^2 ).
Weight and height will be measured by research staff blinded to the participant's randomization group at baseline and 6-months.
Participants will be weighed in light indoor clothing, without shoes, rounding up to the nearest 0.1 kg; height will be measured in a standard manner, without shoes, using a stadiometer, rounding up to the nearest 0.1 cm.
All measures will be performed and recorded twice in succession.
|
6 months
|
Change in body weight in kilograms (kg)
Time Frame: 6 months
|
Participants will be weighed in light indoor clothing, without shoes, rounding up to the nearest 0.1 kg.
All measures will be performed and recorded twice in succession.
|
6 months
|
Change in percent body fat
Time Frame: 6 months
|
Dual Energy X-Ray Absorptiometry (DEXA) scans will be performed at baseline and 6-months.
The DEXA measurements will be made with a Hologic scanner (Hologic 4500 with a "Discovery" upgrade, Hologic Inc, Waltham, Mass).
A whole-body scan takes approximately 10 minutes to complete.
We will measure percent body fat utilizing DEXA.
|
6 months
|
Change in breast tissue markers
Time Frame: 6 months
|
We will collect a breast tissue biopsy from the unaffected breast at baseline and 6 months.
Six slides will be made from each specimen for immunohistochemistry, as follows: Ki67 (MIB-1, DAKO), IGF1 receptor (1D5; DAKO), insulin receptor (mouse anti-human monoclonal B1445; LifeSpan BioSciences), Estrogen receptor (SP1, NeoMarker), Progesterone receptor (pgR636, DAKO) and HER-2 neu (SP3, NeoMarker).
Ki67 will be scored quantitatively (% positive nuclei) using the Aperio system (Specialized Histopathology Laboratory).
Estrogen and progesterone receptors will be scored following current ASCO/CAP guidelines (percent positive, intensity).
Her2 will be scored according to current ASCO/CAP guidelines (intensity of membrane staining).
All other markers will be scored on a semi-quantitative scale (0 to 3+).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fasting insulin
Time Frame: 6 months
|
All the hormones to be measured (insulin, IGF-1, leptin, adiponectin and C-reactive protein) have been previously measured in our lab and published.
We will use immunoassay techniques and kits from Diagnostic Products Corporation (DPC, Los Angeles, CA) to measure each hormone value.
Each woman's baseline and follow-up samples will be used in the same batch, and an equal number of intervention and control samples will also be included in the same batch.
Blind duplicates are also included in and between batches to estimate coefficient of variations.
|
6 months
|
Change in Leptin
Time Frame: 6 months
|
All the hormones to be measured (insulin, IGF-1, leptin, adiponectin and C-reactive protein) have been previously measured in our lab and published.
We will use immunoassay techniques and kits from Diagnostic Products Corporation (DPC, Los Angeles, CA) to measure each hormone value.
Each woman's baseline and follow-up samples will be used in the same batch, and an equal number of intervention and control samples will also be included in the same batch.
Blind duplicates are also included in and between batches to estimate coefficient of variations.
|
6 months
|
Change in C-reactive protein
Time Frame: 6 months
|
All the hormones to be measured (insulin, IGF-1, leptin, adiponectin and C-reactive protein) have been previously measured in our lab and published.
We will use immunoassay techniques and kits from Diagnostic Products Corporation (DPC, Los Angeles, CA) to measure each hormone value.
Each woman's baseline and follow-up samples will be used in the same batch, and an equal number of intervention and control samples will also be included in the same batch.
Blind duplicates are also included in and between batches to estimate coefficient of variations.
|
6 months
|
Skin Carotenoids Assessment
Time Frame: 6 months
|
Assessment of skin carotenoids will be done using Resonance RAMAN Spectroscopy (RRS).
Briefly, a small scanner which shines blue light is placed on the palm of the hand for 30 seconds.
The palm is cleaned with an alcohol wipe prior to the scan, A RRS reading is available after a further 30 seconds.
The procedure is repeated at the same body location.
Skin color is self assessed by the participants at the baseline visit using samples that are used in plastic surgery to assess skin color.
Melanin content (skin color) may have a small effect on RRS, but this effect is minimized by assessing skin carotenoids in the palm, which has a lower melanin content than other body sites.
|
6 months
|
Maintenance of Weight Loss
Time Frame: 12 months
|
A mailed follow up will be conducted at 12-months post randomization.
Questionnaires will be mailed to the participant with a pre-paid envelope for their return.
Information about current weight will be collected using this method.
|
12 months
|
Changes in salivary cortisol
Time Frame: 6 months
|
Women will be asked to collect 3 saliva samples (wake up, midday and bedtime) for 4 days following the baseline biopsy visit and 6 month follow up visit.
Samples will be collected using Salivettes for cortisol.
The cotton ball is removed from the Salivette, chewed for 1 minute and returned to the Salivette.
Samples will be refrigerated in the container provided.
Samples will be returned by mail in a specialized self-addressed pre-paid envelope when sample collection is complete.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Physical Activity
Time Frame: 6 months
|
The 7-Day Daily Activity Log (7-Day DAL) will be the primary measure used to compare physical activity levels at baseline and 6-months among the three groups.
All participants will complete the log for seven consecutive days, recording the amount of time spent in moderate- to vigorous-intensity recreational exercise.
We will calculate their total minutes per week of exercise.
Participants randomized to in-person and telephone counseling will also complete the 7-day DAL weekly.
|
6 months
|
Change in Dietary Intake
Time Frame: 6 months
|
The endpoint measures of diet change will be mean, group level changes in daily caloric intake, based on a 120-item food frequency questionnaire (FFQ) which was developed for the Women's Health Initiative Study and has been validated against 4-Day Food Records and 24-hour Dietary Recalls.
FFQs will be administered at baseline and 6-months.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Melinda L Irwin, PhD, MPH, Yale University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2013
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
April 7, 2014
First Submitted That Met QC Criteria
April 9, 2014
First Posted (Estimate)
April 10, 2014
Study Record Updates
Last Update Posted (Estimate)
February 20, 2023
Last Update Submitted That Met QC Criteria
February 17, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1012007780_1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Weight Loss Counseling
-
Stanford UniversityTerminatedOverweight | Miscarriage | Obese | Recurrent Pregnancy LossUnited States
-
UKK InstituteFinnish Institute of Occupational Health; Academy of Finland; Vitalmed Research...CompletedEffects of Weight Reduction on Sleep and Alertness in Long-distance Truck and Bus Drivers (SF-Truck)Abdominal ObesityFinland
-
Kaiser PermanenteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Wayne State UniversityUniversity of Michigan; Barbara Ann Karmanos Cancer InstituteUnknown
-
Yale UniversityCompleted
-
Wake Forest University Health SciencesNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
The Miriam HospitalCompleted
-
Yale UniversityCompletedWeight Loss | Overweight and Obesity | Food AddictionUnited States
-
Milton S. Hershey Medical CenterNot yet recruitingWeight Loss | Virtual Reality | Implementation Science | Fatty Liver, Nonalcoholic
-
University of OuluUnknownObesity | Cardiovascular Disease | Overweight | Metabolic SyndromeFinland